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Abstract
Background: Insulin- like peptide 3 (INSL3) is a constitutive, secreted peptide pro-
duced in the male uniquely by the Leydig cells of the testes. It is a biomarker for Leydig 
cell functional capacity, which is a measure of the numbers and differentiation status 
of these steroidogenic cells and lacks the biological and technical variance of the ster-
oid testosterone. This retrospective study was carried out to examine the relationship 
between seminal parameters and the Leydig cell compartment, and secondarily to 
assess other factors responsible for determining Leydig cell functional capacity.
Methods: INSL3 was assessed together with seminal, anthropometric, and hormonal 
parameters in a Swedish cohort of 18- year- old men, representing the average popula-
tion, and in a smaller, more heterogeneous cohort of men visiting an Australian infer-
tility clinic.
Results and discussion: Average INSL3 concentration at 18 years is greater than that 
reported at younger or older ages and indicated a large 10- fold variation. In neither 
cohort was there a relationship between INSL3 concentration and any semen pa-
rameter. For the larger, more uniform Swedish cohort of young men, there was a sig-
nificant negative relationship between INSL3 and BMI, supporting the idea that adult 
Leydig cell functional capacity may be established during puberty. In both cohorts, 
there was a significant relationship between INSL3 and FSH, but not LH concentra-
tion. No relationship was found between INSL3 and androgen receptor trinucleotide 
repeat polymorphisms, reinforcing the notion that Leydig cell functional capacity is 
unlikely to be determined by androgen influence alone. Nor did INSL3 correlate with 
the T/LH ratio, an alternative measure of Leydig cell functional capacity, supporting 
the view that these are independent measures of Leydig cell function.
K E Y W O R D S
hypothalamic- pituitary- gonadal axis, insulin- like peptide 3, Leydig cell functional capacity, 
male fertility
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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1  |  INTRODUC TION
Recent publications have highlighted a possible link between Leydig 
cell functionality and male fertility.1– 7 Whilst it is well established 
that testosterone produced by Leydig cells is essential for the pro-
gression of spermatogenesis via its effects on Sertoli cells, what is 
not clear is whether a moderate disruption or defect in the Leydig 
cell compartment independently of testosterone might be partly 
responsible for reduced sperm numbers and/or motility. The situ-
ation is confused since both the interstitial and seminiferous com-
partments are under the homeostatic control of the HPG axis via 
a common GnRH pathway and the anterior pituitary hormones LH 
and FSH, respectively.8 So, for example, in classical hypothalamic 
hypogonadism, a reduction of gonadotropin production leads to loss 
of both spermatozoa and testosterone. Moreover, the integrity of 
the two compartments could be developmentally linked via their 
joint and/or mutual relationship in the context of the testicular dys-
genesis syndrome, whereby it is postulated that prenatal endocrine 
disruption might impact the differentiation of both spermatogenic 
and steroidogenic components.9 Extensive results of semen and 
hormonal analyses in young men and infertility patients show that 
within the normal range there appears to be no correlation between 
circulating testosterone (T) and any semen parameter.4 However, 
there does appear to be a negative association between circulating 
LH and sperm concentration.4 This would imply that the resulting 
normalized testosterone concentration may be the result of a com-
pensated Leydig cell dysfunction, which is reflected by the ratio 
of T/LH. The latter parameter has been referred to elsewhere as 
Leydig cell functional capacity and is thought to reflect the number 
and functionality of the Leydig cells.1,2 For example, dysfunctional 
Leydig cells might have impaired LH receptor signalling, leading to a 
reduced T biosynthesis for a given concentration of LH.
Insulin- like peptide 3 (INSL3) is also a hormone synthesized and 
secreted into the bloodstream uniquely by testicular Leydig cells. 
Importantly, its production is largely constitutive and acutely inde-
pendent of the hypothalamic- pituitary- gonadal (HPG) axis. Unlike 
steroids, such as testosterone, whose synthesis and secretion is reg-
ulated within minutes by LH, INSL3 is not altered by LH (or hCG) 
within this time frame10 but only after days or weeks, when the go-
nadotropin may influence the proliferation and/or differentiation of 
Leydig cells.11 Consequently, INSL3 is a reliable biomarker for the 
number and mature differentiation status of the Leydig cells.11 In 
other words, it is also a measure of Leydig cell functional capacity. In 
order to explore whether the Leydig cell compartment rather than 
the HPG axis could indeed be directly influencing spermatogenesis 
in adult men, two independent cohorts were analysed retrospec-
tively for circulating INSL3, together with other reproductive hor-
mones and a range of seminal parameters. One cohort comprised 
303 young men aged 18 years and of unknown fertility, called up for 
military service in Sweden, and representing a cross- section of the 
Swedish male population.12,13 A second cohort comprised 43 men 
(aged 26– 53 years) attending an Australian infertility clinic with an 
average duration of infertility of 2.5 ± 0.6 years. These men had been 
recruited for a trial of an antioxidant preparation14 and were similarly 
assessed for seminal, hormonal and anthropometric parameters.
T Swedish c hort f 18- year- old men also allowed a se ondary 
aim of comparing INSL3 values at 18 years w th those estimated in 
older and you ger individuals of simila  ethnic and geographic back-
ground. Detailed studi s in rats have shown that circulating INSL3 
concentration reaches a peak at around 6 weeks (the time when 
mature sp rmatozo  are first evident in th  epididymis) and subse-
quently declines to stable lower mean levels by about 3 months.10 
For the human, several studies of boys undergoing puberty show 
that maximal INSL3 value  have probably not been attained by 
Tanner stage 5 (aged ca. 14– 17 years).15– 17 Also, another study has 
indicated that INS 3 con ntr tion declines steadily from a e 35– 
40 to old age (80+ years).18 There is little detailed information about 
mean INSL3 conc ntr tion at an intermediate age b tween puberty 
and stablish d adulthood, though one recent study of Danish men 
has supp rted higher INSL3 values in young adulthood.19
Whilst the primary aim of this retrospective study was to assess 
the relationship between seminal parameters and Leydig cell func-
tional capacity, the parameters available also allowed a third aim 
of determining possible factors linked to the large inter- individual 
variation in circulating INSL3 measured. Besides se inal, anthropo-
metric and hormonal parameters, the Swedish cohort of 18- year- old 
men was also assessed for androgen receptor polymorphisms to elu-
cidate a further possible interaction with androgen action. In this 
association study, INSL3 was compared with testosterone, since it 
has recently been suggested that INSL3 is an important new clini-
cal measure of Leydig cell function, which differs from and comple-
ments testosterone.20
2  |  MATERIAL S AND METHODS
2.1  |  Subjects
The Swedish cohort of 305 young men (Table 1A) called up for mili-
tary service and representing the southern Swedish population has 
been described in detail before.12 They are representative of 95% 
of the male population and exclude only individuals with severe 
medical conditions. Of these 305 subjects, average age 18.2 years 
and mean BMI (weight/height2) of 22.6 + 3.2 kg/m2, the majority 
(248) were born and raised in Sweden. Serum samples were only 
available for INSL3 analysis from 303 of them. Smoking habits were 
ascertained from a questionnaire.12 Physical examination also in-
cluded the estimation by ultrasound of left and right testis volume. 
Scanning made use of a 7.5- MHz transducer connected to an Aloka 
900 SSE scanner (Aloka, Tokyo, Japan) in two projections; volume 
was calculated as length × width × depth × 0.52.21 Mean and median 
parameters are indicated in Table 1A.
Additionally, 271 serum samples from older men within the 
general population and without severe illness were available for 
the measurement of INSL3 from the second phase of the European 
Male Aging Study, all collected at the same centre in Sweden as the 
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Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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military conscripts, and representing the same southern Swedish 
population.22,23 Relevant mean and median parameters are pre-
sented in Table 1B. The data for INSL3 included in Figure 1B for 
boys going through puberty are redrawn from Johanssen et al.17 and 
represent a longitudinal pilot cohort from the Copenhagen area of 
Denmark. Data were obtained from 10 boys of Caucasian ethnicity 
TA B L E  1  Average descriptive, semen and hormone parameters
Parameter Mean ± SD (n) Median (25%, 75% quartiles) Reference limits
A. Swedish cohort of military conscripts
Age (years) 18.2 ± 0.4 (305) 18.2 (18.1, 19.2) NA
BMI 22.56 ± 3.17 (303) 22.20 (20.80, 23.60) 18.5– 24.9
Sperm concentration (×106/ml) 72.17 ± 66.44 (301) 53.80 (28.15, 94.90) >15 × 106
Sperm motility (CASA, %) 50.8 ± 22.0 (286) 51.0 (35.0, 68.0) >32%
Semen volume (ml) 3.21 ± 1.31 (302) 3.2 (2.3, 4.0) >1.5
DNA fragmentation index (%) 13.60 ± 8.99 (278) 11.14 (7.64, 15.98) <20%
Left testis vol (US, ml) 14.19 ± 3.98 (305) 13.5 (11.5, 16.8) NA
Right testis vol (US, ml) 14.84 ± 4.14 (304) 14.5 (11.7, 17.8) NA
INSL3 (ng/ml) 2.15 ± 0.86 (302) 2.02 (0.74, 2.52) NA
Total testosterone (nmol/L) 22.95 ± 5.33 (304) 23.00 (19.4, 27.0) 8.7– 33.0
LH (IU/L) 4.3 ± 1.6 (304) 4.14 (3.18, 5.28) 1.2– 9.6
FSH (IU/L) 3.4 ± 1.7 (304) 3.15 (2.20, 4.20) 1.0– 10.5
T/LH ratio 5.96 + 2.39 (304) 5.56 (4.28, 7.19) NA
SHBG (nmol/L) 28.46 ± 9.65 (304) 28.0 (22.0, 34.0) 13– 50
Inhibin B (ng/L) 209.1 ± 61.6 (304) 200.0 (166.3, 251.0) 100– 240
AR no. CAG repeats 22.19 ± 2.96 (298) 22.0 (20.0, 24.0) NA
AR no. GGN repeats 16.63 ± 2.49 (224) 17.0 (17.0, 18.0) NA
B. Swedish cohort of men enrolled in the second phase of the EMAS study
Age (years) 63.3 ± 10.6 (271) 61.6 (54.7, 72.4) NA
BMI 27.31 ± 4.13 (252) 27.0 (2.4, 29.9) 18.5– 24.9
INSL3 (ng/ml) 0.96 ± 0.49 (271) 0.84 (0.63, 1.16) NA
Total testosterone (nmol/L) 15.93 ± 6.31 (271) 14.71 (11.77, 19.71) 8.7– 33.0
LH (IU/L) 6.39 ± 4.78 (229) 5.32 (3.87, 7.18) 1.2– 9.6
T/LH ratio 3.21 ± 1.98 (229) 2.81 (1.97, 3.95) NA
C. Australian men attending an infertility clini
Age (years) 39.0 ± 6.1 (40) 38.0 (35.0, 43.0) NA
BMI 29.31 ± 3.86 (30) 28.6 (26.7, 32.7) 18.5– 24.9
Sperm concentration (×106/ml) 32.54 ± 40.53 (40) 19.3 (12.0, 33.9) >15 × 106
Sperm motility (%) 36.2 ± 12.5 (40) 38.5 (29.0, 45.0) >32
Semen volume (ml) 3.07 ± 1.83 (40) 2.65 (1.80, 4.00) >1.5
Sperm normal morphology (%) 6.35 ± 4.88 (40) 5.00 (2.00, 9.75) >4
DNA fragmentation index (%) 22.55 + 8.52 (40) 22.55 (16.53, 25.93) <20
ROS (µg formazan/107 sperm) 81.20 + 61.33 (40) 66.5 (45.5, 94.0) NA
INSL3 (ng/ml) 1.78 ± 0.82 (43) 1.52 (1.25, 2.16) NA
Total testosterone (nmol/L) 13.84 ± 3.93 (40) 14.1 (10.9, 15.6) 8.7– 33.0
LH (IU/L) 4.33 ± 1.53 (40) 4.00 (5.00, 5.23) 1.2– 9.6
FSH (IU/L) 5.52 ± 2.81 (40) 5.45 (3.18, 7.08) 1.0– 10.5
T/LH ratio 3.53 ± 1.46 (40) 3.10 (2.48, 4.68) NA
AMH (pmol/L) 63.42 ± 29.65 (38) 64.10 (37.28, 88.88) 5– 140
Note: Average relevant descriptive, semen and hormone parameters for (A) the Swedish cohort of military conscripts, (B) the Swedish component 
of the European Male Aging Study (second phase), (C) the Australian cohort of men attending an infertility clinic. Relevant reference limits are also 
included. NA, not applicable.
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Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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followed for several years from before and during puberty with reg-
ular blood sampling, as described previously.17
Serum was also available from 43 participants at entry from a 
study involving men recruited at an Australian infertility clinic to 
investigate the effects of antioxidant treatment on semen param-
eters.14 Altogether 50 men had been recruited with entry criteria 
of at least one million sperm per millilitre in their ejaculate and ev-
idence of seminal oxidative stress. The average age of participants 
was 39 years (range 26– 53 years) with an average duration of infer-
tility of 2.5 years. The relevant mean and median parameters are 
presented in Table 1C.
Full ethical approval and patient consent had been obtained 
for all studies, as published,12,14,22,23 including later use of archived 
blood samples for retrospective analyses.
2.2  |  Semen samples and analyses
For the Swedish cohort, semen collection followed 48– 72 hs ab-
stinence and analysis followed WHO guidelines,24 employing 
strict morphological criteria, and has been reported in detail previ-
ously.13,21,25 Sperm concentration was estimated using a Neubauer 
chamber and percentage sperm motility was assessed by CASA 
using the CRISMAS system as previously described.25 Sperm DNA 
damage was assessed by the DNA fragmentation index (DFI), as 
described,13 based on the proportion of acridine orange red fluo-
rescence (single- stranded DNA) measured by FACS. The Australian 
samples measured sperm concentration and semen volume as 
above. Sperm motility and morphology were assessed microscopi-
cally according to WHO guidelines,24 as above. TUNEL was used to 
assess DNA integrity employing the In situ Cell Death Detection Kit 
(Roche Diagnostics GmbH, Mannheim, Germany) to detect single- 
strand breaks.14 The DNA fragmentation index (DFI) was calculated 
as the percentage of TUNEL- positive nuclei (FITC- labelled, green) 
per total number of sperm nuclei (propidium iodide, red). Reactive 
oxygen species (ROS) was measured by a modified colorimetric 
nitroblue tetrazolium assay,14 recording results as the intracellular 
product formazan in µg per 107 sper atozoa.
2.3  |  Androgen receptor trinucleotide 
repeat analysis
The N- terminal domain of the androgen receptor encoding the 
transactivation region is subject to marked polymorphism due to 
two trinucleotide repeat elements. Extremely long and short lengths 
of the poly- glutamine encoding CAG repeat are linked to Kennedy's 
disease with reduced androgen responsiveness and male infertility26 
and in vitro even modest variation in length can affect androgen re-
ceptor function.27 The more downstream GGN repeat element has 
not been well studied and does not appear to associate with any 
phenotypic trait.28 Since Leydig cell function may be directly influ-
enced by androgen action, both CAG- and GGN repeat lengths were 
determined by nested PCR using flanking gene- specific oligonucleo-
tide primers, followed by sequencing of PCR products, as previously 
described in detail,13,28 and retrospectively compared to Leydig cell 
functional capacity as represented by INSL3 concentration in the 
circulation.
2.4  |  Hormone analyses
For the Swedish cohort of young men, FSH, LH, total testosterone (T) 
and SHBG were measured by automated fluorescent immunoassay 
(Autodelfia; Wallac Oy, Turku, Finland) at the routine clinical chem-
istry laboratory at Uppsala University Hospital.13 Intra- and total 
assay variation for these parameters was <4.0% and <7.5%, respec-
tively. Free testosterone (FT) was estimated from the concentrations 
F I G U R E  1  (A) Scatterplot of peripheral INSL3 concentration in 303 young men aged 18 years called up for military service in southern 
Sweden. INSL3 expressed using Log2 scale (mean ± SD). (B) Age distribution for circulating INSL3, based on three independent cohorts (aged 
<16 years from the Danish puberty pilot study17; aged 18 years from A; aged >40 years from phase 2 of the Malmo subcohort of the EMAS 
study22,23) using the same TRFIA assay and controls (means ± SEM; for details see text)
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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of total testosterone and SHBG29 and Inhibin B made use of a spe-
cific immunometric assay with a detection limit of 15 ng/L and intra- 
assay and total ass y variation coefficients <7%.30 For the Australi n 
cohort, with the exc pt on f AMH (see below), all hormone assays 
used the automated ADVIA e taur chemiluminescent immunoas-
say system (Bayer Australia Ltd; Pymble, NSW, Australia). For LH and 
FSH, the limit of detection was 0.1 and 0.3 IU/L, resp ctively, with 
intra- and total a say coefficients of variation of <4.0%. For testos-
terone, the limit of detection was 0.35 nmol/L, with intra- a d total 
assay coefficie ts of variation of <6% and <9%, respec ively. Serum 
AMH on entration was m asured by Immunotech high- sensitivity 
immuno- enzym tric assay (Beckman oulter, Marseille, France). The 
sensitivity of this assay was 0.7 pmol/L; intra- and total assay coef-
ficients of variation were ≤12.3% and ≤14.2%, respectively.
INSL3 was meas r d in all cohorts by time- resolved fluorescent 
im unoassay, as previously describ d.11 We have previously s own 
that the concentration of this peptide hormone is quantitatively sta-
ble over many years when stored frozen at – 20°C and subjected to 
several freeze- thaw cycles.11 Importantly, for all the assays reported 
here, the same internal standards were used, as well as identical ex-
ternal control male serum samples. The limit of detection of this assay, 
as used, was 20 pg/ml with intra- and total coefficients of variation of 
<3% and <8%, respectively. Recently, this assay was directly compared 
with a new LC- MS/MS procedure with almost identical results.31
2.5  |  Statistical analysis
Data were first explored for outliers and associations using scat-
ter plots and simple correlation analysis, and descriptive statistics 
computed for each variable. INSL3 and total testosterone (T) were 
each considered as response (dependent) variables. Multiple linear 
regression analysis was fitted for each of the response variables 
using the parameters listed in Table 1 as independent variables. 
Known essential variables and potentially useful subsets of ex-
planatory variables were first selected from the list. A combination 
of stepwise regression, forward selection and backward elimina-
tion was used to identify the best final model, with best fit being 
assessed using the adjusted R- square criterion. Multicollinearity 
among variables was checked using the variance inflation factor 
(VIF). Consequently T, but not FT, nor the T/LH ratio were included 
in the models. Assumptions of multiple regression were checked 
using residuals. Variables were transformed when assumptions of 
normality and constancy of variance were violated. Only INSL3 
needed to be log- transformed as dependent variable. Parameter 
estimates of variables with statistically significant contribution 
at the 5% level of significance to the prediction of the depend-
ent variable are reported. Few variables with 10% level of statisti-
cal significance were left in the final model to inform the reader 
of the potential significance of the variables in further study. An 
independent variable with a negative model coefficient indicates 
that it has an inverse association with the dependent variable (that 
is, when one increases, the other decreases). The standardized 
regression beta coefficient compares the strength of the effect of 
each individual independent variable to the dependent variable. 
The higher the ab olute value of t  beta coefficient, the stronger 
the effect. For a proper interpretation of a model fitted on a log- 
transfor ed response variable, the parameter estimates s ould be 
first back- transformed to the origin l units by taking the exponent
of the model coeff cient for each variable. T adjusted coefficient 
of determination (R2) is reported to show the amount f variation 
in the dep ndent variable that is explained by the independent 
variables of th  model, along with the p- values of the ANoVA show-
ing the s atistical significance of the final model. Dat  wer  ana-
lysed using Graphpad Prism version 8.2 and spss (IBM spss Statistics 
26) software. The data for trinucleotide re eats were compared by 
ANoVA followed by Neumann- Keuls post hoc test.
3  |  RESULTS
3.1  |  D scriptive parameters for the Swedish and 
Australian cohorts
Table 1A shows mean and median data for the Swedish cohort of 
military conscripts. These are of a very close age range and predomi-
nantly healthy, with mostly low BMI, modest smoking prevalence 
(28.8% smokers), and seminal parameters within the normal range. 
Similarly, hormonal parameters are also within the normal range. For 
the Australian men attending an infertility clinic (Table 1C), these 
are older men, with higher BMI, mixed to poor semen parameters, 
including a higher mean DNA fragmentation index and evidence of 
oxidative stress. Testosterone is reduced compared to the Swedish 
cohort and gonadotropins are elevated. Table 1B shows parameters 
available for the second phase cohort of older men recruited as part 
of the EMAS study and used for comparison only.
3.2  |  INSL3 concentration in 18- year- old men 
represents peak post- pubertal levels
Applying the same validated INSL3 assay that has been used for 
studies of puberty and ageing (including identical positive control 
blood samples), we show here that mean INSL3 concentration in 
18- year- old Caucasian men is substantially greater at 2.15 ± 0.86 ng/
ml (mean ± SD) than in late adolescence (1.37 ± 0.55 ng/ml at Tanner 
stage 5), or after 40 years (1.18 ± 0.49 ng/ml at mean 47.5 years; 
Figure 1A and B). The data for ageing men in Figure 1B represent 
men from the same district of Sweden analysed as part of the EMAS 
study23 (R Anand- Ivell & R Ivell, unpublished). This suggests a profile 
of Leydig cell development largely similar to that observed in rats, 
with maximal Leydig cell functional capacity evident in young adult-
hood (ca. 18 years). Also evident from this cohort is that there is a 
similar approximately 10- fold range of INSL3 values (0.74– 8.2 ng/
ml) in 18- year- old men as is observed in the larger ageing male 
population.18
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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3.3  |  Lack of relationship between INSL3 and 
seminal parameters
Both in the Swedish cohort of 18- year- old young men, as well as in the 
Australian men attending an infertility clinic, initial correlation analy-
sis showed that there was no significant association between INSL3 
and any sperm- related parameter (sperm concentration, total sperm 
number, ejaculate volume, progressive motility and DNA fragmenta-
tion index). For testosterone as dependent variable, the final multiple 
regression model suggested, for the larger Swedish cohort of young 
men, a significant negative association with sperm concentration 
(p = 0.011) though for no other sperm- related parameter (Table 2); for 
the final multiple regression model of the smaller Australian cohort, 
testosterone failed to show this association, though did indicate a sig-
nificant positive relationship to the DNA fragmentation index (DFI; 
p = 0.017; Table 3). Substituting free testosterone as dependent or 
independent variable in the multiple regression analysis had no quali-
tative effect on the relationships described above (not shown).
3.4  |  Correlation between INSL3 and systemic 
hormo al and clinical parameters
For the Swedish cohort of 18- year- old men from the gener l popula-
tion, as expected, the best model showed a significant association 
between INSL3 and tot l T (p < 0.001; Table 2). There wa  also a sig-
nificant positive association with FSH (p = 0.002; Table 2), thoug  not 
with LH. In the pr liminary correlation analysi , INSL3 concentration 
showed no correlation with the T/LH ratio, and a negative trend wit  re-
ported smoking incidence, which was kept in the final model (p = 0.094; 
Table 2). INSL3 was also significantly negatively ssociated with BMI 
(p = 0.013; Table 2), I hibin B (p = 0.030; Table 2), and positively with 
average testis size measured by ultrasound (p < 0.003; Table 2), even 
though the Leydig cell compartment comprises less than 10% of testis 
volume, the bulk being made up of the spermatogenic compartment. 
Note that the model was fitted to the transformed values of INSL3, and 
hence, the coefficients should be first back- transformed using exp(B) 
for the purpose of interpretation. For total T, for instance, this becomes 
exp(0.017) = 1.02. That means, if all other variables in the model are 
held constant, for a unit increase in total T, the value of INSL3 increases 
by 2%. For BMI, exp(−0.016) = 0.98, indicating a 2% reduction in INSL3 
concentration for each unit increase in BMI.
In the final multiple regression model, T was significantly as-
sociated with LH in this study (Table 2; p < 0.001), though showed 
no relationship towards FSH. In the final model, total T was also 
TA B L E  2  Multiple regression analysis of the Swedish cohort of 
young men
Model B Std. Error Beta t p- value
(A) Dependent variable: lnINSL3
(Constant) 0.306 0.227 1.350 0.178
Smoking −0.071 0.042 −0.091 −1.679 0.094
T 0.017 0.004 0.260 4.048 <0.001
Inhibin B 0.001 <0.001 0.141 2.180 0.030
FSH 0.040 0.013 0.194 3.063 0.002
BMI −0.016 0.006 −0.145 −2.488 0.013
Avg. testis 
vol.a 
0.016 0.005 0.175 3.026 0.003
(B) Dependent variable: T
(Constant) 15.965 3.175 5.029 <0.001
LH 0.887 0.180 0.261 4.915 <0.001
SHBG 0.264 0.031 0.480 8.607 <0.001
BMI −0.212 0.090 −0.132 −2.359 0.019
Avg. testis 
vol.a 
0.211 0.078 0.154 2.689 0.008
No. GGNb  −0.210 0.121 −0.094 −1.766 0.079
lnINSL3 2.177 0.834 0.140 2.609 0.010
Sperm conc. −0.011 0.004 −0.141 −2.555 0.011
Note: (A) This optimal model accounts for 14.0% (adjusted R2) of 
variability in lnINSL3 (p < 0.001). (B) This optimal model accounts for 
40.9% (adjusted R2) of variability in total testosterone (p < 0.001). 
Optimal coefficients for the final multiple regression models of the 
Malmo cohort of 18- year- old young men with either lnINSL3 (log- 
transformed INSL3) or total testosterone (T) as dependent variables.
Abbreviations: Avg. testis vol, represents the mean of left and right 
testis volumes determined by ultrasound; BMI, body mass index; No. 
GGN, represents the sequence length of the GGN trinucleotide repeat 
in the androgen receptor gene; SHBG, serum hormone- binding globulin.
aAvg. testis vol. represents the mean of left and right testis volumes 
determined by ultrasound. 
bNo. GGN represents the sequence length of the GGN trinucleotide 
repeat in the androgen receptor gene. 
TA B L E  3  Multiple regression analysis of Australian men 
attending an infertility clinic
Model B
Std. 
Error Beta t p- value
(A) Dependent variable: lnINSL3
(Constant) −0.544 0.214 −2.536 0.016
T 0.053 0.014 0.496 3.840 <0.001
FSH 0.059 0.019 0.398 3.088 0.004
(B) Dependent variable: T
(Constant) 13.923 4.851 2.870 0.008
lnINSL3 4.033 1.299 0.416 3.104 0.005
BMI −0.348 0.151 −0.313 −2.304 0.030
AMH 0.063 0.019 0.451 3.307 0.003
DFI 0.190 0.074 0.359 2.560 0.017
Note: (A) This optimal model accounts for 40.5% (adjusted R2) of 
variability in lnINSL3 (p < 0.001). (B) This optimal model accounts for 
50.5% (adjusted R2) of variability in total testosterone (p < 0.001). 
Optimal coefficients for the final multiple regression models of the 
Australian cohort of men attending an infertility clinic with either 
lnINSL3 (log- transformed INSL3) or total testosterone (T) as dependent 
variables.
Abbreviations: AMH, Anti- Mullerian Hormone; BMI, body mass index; 
DFI, DNA fragmentation index measured by TUNEL.
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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associated with SHBG (p < 0.001), BMI (p = 0.019), average testis 
size (p = 0.008), lnINSL3 (p = 0.010) and with an association trend in 
regard to the number of GGN trinucleotide AR repeats (p = 0.079).
Ass ssing all baseline (pre- antioxidant therapy) parameters in 
the smaller, more heterogeneous Austr lian cohort showed th t, as 
for the Swedish cohort, INSL3 in the final model was stron ly asso-
ciated with total T (Table 3; p < 0.001). INSL3 was also associated 
with FSH (Tabl  3; p = 0.004), though not w t  any other parameter. 
Apart from an asso iation with AMH (Table 3; p < 0.003), T showed 
no significant association with a y other paramet r ex ept INSL3 
(Table 3; p = 0.005), BMI (Table 3; p = 0.030) and the sperm DNA 
fragm ntation index measured by TUN L (Table 3; p = 0.017).
As indicated previously,13 whereas 3 months of antioxidant treat-
ment appeared to impr ve some seminal parameters dependent on 
oxidative stress, it had no effect on any hormonal para eter, also 
now including INSL3 concentration, which was not differe t within 
indivi uals between pre- and post- antioxidant treatment (mean ± 
SEM: pre: 1.78 ± 0.13 ng/ml; post: 1.77 ± 0.12 ng/ml). In fact, re-
flecting what had been shown previously for the within- individual 
consistency of INSL3 over time,10 the individual values measured at 
entry and completion of the antioxidant trial after 3 months were 
very similar (r = 0.656, p < 0.001).
3.5  |  Lack of relationship between INSL3 
expression and androgen receptor variants
For the Swedish cohort, data were also available in regard to the pres-
ence of common androgen receptor polymorphisms, represented by 
two trinucleotide repeat regions within the androgen receptor gene. 
Longer or shorter repeat regions have been associated with subop-
timal androgen responsiveness32,33 and some reproductive param-
eters.27,34,35 No association was evident between circulating INSL3 
concentration and shorter or longer trinucleotide repeat variants of 
the androgen receptor (Figure 2). The CAG repeat number did indi-
cate an independent negative correlation with total sperm number 
(r = −0.141, p = 0.015; not shown) as well as positively with LH con-
centration (r = 0.114, p = 0.046; not shown), though with no other 
parameter in this cohort, whereas the GGN repeat number, other than 
with the CAG repeat number (r = −0.240, p < 0.001; not shown), did 
correlate with semen volume (r = 0.187, p = 0.005; not shown) and 
indicated a negative trend in regard to T (Table 2; p = 0.079), allowing 
it to be included in the final predictive multiple regression model.
4  |  DISCUSSION
4.1  |  Maximal Leydig cell functional capacity is 
achieved in early adulthood
Whilst individual Leydig cells mostly appear neither to divide 
nor to die during normal adult life, there does appear in vivo to 
be a decline in 3betaHSD2 stainable interstitial cells and overall 
INSL3 gene expression with increasing age,36 suggesting either a 
reduction of Leydig cell numbers or their differentiation status, 
even though in vitro such older cells still appear to be as steroi-
dogenic and responsive to gonadotropins as younger ones.36 The 
functional capacity of Leydig cells to produce hormones like tes-
tosterone or INSL3 in vivo will reflect the total Leydig cell mass 
and their average level of differentiation, which will only change 
slowly over adult lifetime. Both the ratio of naturally circulating T 
to LH, as well as the acute T response to LH or hCG injection, have 
also been suggested as indicators of in vivo Leydig cell functional 
capacity. The biomarker INSL3 is a constitutive and relatively ro-
bust indicator also of Leydig cell functional capacity, acutely inde-
pendent of the HPG axis, with low within- individual and technical 
variance,10,37 and effectively measuring the product of Leydig cell 
numbers and their average differentiation status. It therefore dif-
fers from testosterone whose measurement is associated with 
relatively high technical and biological variance, and whose circu-
lating level is under constant acute feedback correction through 
the phasic hormones of the HPG axis. One consequence of this is 
the peripubertal profile of testosterone in most species, which with 
increasing LH rises to a maximum at the end of puberty, attaining 
a level which is then homeostatically maintained into adulthood38 
F I G U R E  2  Relationship between p ripheral INSL3 concentration 
and length of the CAG- and GGN repeats within the 5′ region of 
the androgen receptor gene. CAG repeat no.: small 13– 20 (n = 90), 
medium 21– 23 (n = 110), long 24– 30 (n = 102); GGN repeat no.: 
small 4– 16 (n = 33), medium 17 (n = 114), long 18– 20 (n = 75). Box 
and whisker plot represents median and 5/95 percentiles
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
8  |    ANAND- IVELL Et AL.
and is compensated by increasing LH as men age.39 INSL3, in con-
trast, rises to a maximum at the end of puberty concomitant with 
the massive increase in LH, but then settles in post- puberty to a 
lower steady- state concentration as pituitary LH declines to more 
stable adult levels.14 During puberty, LH stimulates both the pro-
liferation and differentiation of Leydig cells which appear to attain 
their maximum number in late adolescence. This chronic effect of 
LH is in stark contrast to the acute phasic stimulation by LH of tes-
tosterone production and secretion. In rats, we have shown that 
peak INSL3 coincides with the first appearance of spermatozoa in 
the epididymis, but in humans until recently, we have not had such 
information. Conventionally, in boys, we identify the attainment of 
puberty with Tanner stage 5 at around 14– 17 years. But the pre-
sent study shows that Leydig cell functional capacity continues to 
increase to at least 18 years, before its biomarker INSL3 reduces 
to a lower value at some time within the next decade or so.
Recently, Albrethsen et al.19 published the results of an assess-
ment of INSL3 in several Danish cohorts, using a new LC/MS- MS 
method earlier shown to give very similar results to the INSL3 im-
munoassay used here.31 They showed a similar pattern of INSL3 in-
crease during puberty and young adulthood, as well as a negative 
association with smoking and increasing age. However, in the Danish 
study, the mean and confidence intervals illustrated for young men 
at approximately age 20 appear to be somewhat lower than those 
values reported here for the Swedish 18- year- old men. It should be 
recalled that there appear to be substantial differences in some an-
drological parameters between otherwise comparable Danish and 
Swedish men,12 with the first having significantly worse semen pa-
rameters. Since Sertoli and Leydig cell numbers in the human testis 
appear to correlate closely,36 with the former largely responsible for 
supporting spermatogenesis, this would imply that the INSL3 refer-
ence values given in the article by Albrethsen et al.19 may only be ap-
propriate for Danish subjects. Further research on INSL3 geographic 
variation will be important to help clarify some of these issues.
The uniform age of the Swedish cohort means that any associa-
tions evident between parameters can be assessed free of any age- 
dependent confounding factors, which can add substantial variance 
to this kind of analysis. For the Swedish cohort of 18- year- old men, 
INSL3 did not correlate significantly with the T/LH ratio, nor was 
there was any relationship between these parameters for the 
smaller, more heterogeneous Australian cohort, even after correct-
ing for age and/or BMI, implying that other factors are influencing 
the T/LH ratio compared to INSL3. Moreover, and in agreement 
with Toppari,20 INSL3 appears to provide a different measure of 
Leydig cell function compared to T or the T/LH ratio, perhaps re-
flecting chronic rather than acute Leydig cell functional capacity.
4.2  |  Lack of association between Leydig cell 
functional capacity and semen parameters
A key finding of the present study, involving two separate cohorts 
of men, is that we find no relationship at all between Leydig cell 
functional capacity, reflected by circulating INSL3 concentration, 
and male fertility potential evidenced in standard seminal param-
eters. There is substantial inter- individual variance in INSL3 con-
centration in young men, and elsewhe e, it ha been shown that 
this is a good predictor of morbidity as men age, since it correlates 
not only with test sterone, but also with moking, obesi y, diabe-
tes, cardiovascular disease a d bone density40 (R Anand- Ivell & R 
Iv ll, unpub ished). In erestingly, seminal parameters have also re-
cently bee  con idered to be good predictors of morbi ity, such 
as the metabolic syndrome.41,42 Logically, therefore, one might 
ave expect d to see a correlation b tween Leydig cell paramet rs 
and those of the seminiferous compartment, specially giv n the 
significant association between Sertoli and Leydig cell numbers.36 
That this is not the case suggests that the associations with mor-
bidity are relativ ly indep ndent ev nts, or that such a relation-
shi  might only pertain to lder subjects. Moreover, the v ry high 
intra- testicular T concentration in eugonadal men would suggest 
that only in extreme hypogonadism could androgen receptors in 
the seminiferous compartment remain unoccupied and be affected 
by changing T concentration.
One reason for this discussion is that it has been shown that 
male fertility parameters may partly be determined early during 
foetal life as a consequence of a postulated testicular dysgenesis 
syndrome, which shares its origins also with the development of 
the Leydig cell compartment and associated androgen produc-
tion.9 Foetal or perinatal exposures to environmental endocrine 
disruptors, maternal pharmaceuticals or other early developmental 
insults appear to impact on stem and progenitor cells within the de-
veloping gonads, leading to impairment of spermatogenesis as well 
as of Leydig cell- dependent physiology, for example, resulting in 
cryptorchidism.43 Moreover, in recent Chinese studies it has been 
shown that both INSL3 and sperm parameters may mutually inter-
act under the negative influence of adult phthalate exposure.44,45 
The findings from the two studies presented here imply that poor 
sperm parameters and Leydig cell functional capacity in young 
adulthood are likely to have a separate postnatal aetiology from 
that caused by a common association in early life, and that lifestyle 
and/or exposures in childhood and adolescence are likely to be 
playing a significant role. In particular, the Swedish study highlights 
the marked negative influence of BMI on chronic Leydig cell func-
tional capacity, reinforcing preliminary findings from a recent study 
looking at late adolescent boys,46 as well as other more diverse co-
horts.19,40 How BMI affects circulating INSL3 levels is not known, 
but unlike for testosterone where the increased levels of aromatase 
in fat tissue will have a directly modifying effect on the circulating 
androgen, it appears more likely that adipose tissue factors may be 
influencing Leydig cell function. Moreover, a recent study in bulls 
has shown a positive effect of a prepubertal high- protein diet on 
both later INSL3 production and the timing of puberty.47 Together, 
such results support a view that healthy prepubertal nutrition may 
positively influence chronic adult Leydig cell functional capacity, 
though a negative influence of other environmental and lifestyle 
stressors cannot be excluded.
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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The lack of association between INSL3 and male seminal param-
eters appears to contradict studies which suggest that INSL3, act-
ing via specific RXFP2 receptors on spermatocytes and spermatids, 
ma  act anti- apoptotically to prevent g rm cell loss. However, this 
relationship has been revealed only in extreme situations of INSL3 
im unization in pigs,48,49 INSL3 antagonist treatment of rats,50 or 
hormonal suppression of the GnRH axis in men.51 For mice in which 
RXFP2 expression has been specifically suppressed in adult m le 
germ cells, there was no evidence for any such positive effect of 
INSL3 o  spermatogenesis.52 It thus appears likely that a role for 
INSL3 to promote germ cell survival may only be relevant in such ex-
treme situations, or maybe during the first wave of spermatogenesis 
in arly prepuberty, wh n intra- testicular INSL3 levels are lower and 
RXFP2 receptors are likely t  be ot des nsitized by the later high 
intra- testicular concentration of INSL3.
4.3  |  Role of FSH in determining Leydig cell 
functional capacity
One of the more interesting findings from the present studies was 
the marked influence of FSH, rather than LH, on INSL3 concentra-
tion. Within the testes, FSH receptors are only found on Sertoli cells 
within the seminiferous compartment. Yet there is no relationship 
between semen parameters and INSL3, nor between the Sertoli cell 
product AMH and INSL3 in the Australian study (not shown). One 
explanation could be simply the lower biological variance associated 
with circulating FSH compared to LH or testosterone, both of which 
exhibit a much more marked pulsatility of expression. But there is 
also the possibility that FSH may be involved in a more direct link to 
Leydig cell function, possibly through the agency of Sertoli cell activ-
ity. This notion would be supported by the association of INSL3 with 
testis size, as well as with Inhibin B, which is largely due to the action 
of FSH on Sertoli cells to promote spermatogenesis. There appears 
to be mutual paracrine regulation of the interstitial and seminiferous 
compartments,5 and it is known that Sertoli cells secrete a number of 
factors, including PDGF,53 which can influence Leydig cell function 
directly through specific PDGF receptors.53 This observation is also 
strongly supported by a recent study in mice, which showed a direct 
link between Leydig cell number and the size of the adult Sertoli cell 
population.54 Similarly, in the human testis, Sertoli and Leydig cell 
numbers appear to correlate.36 An earlier study had shown in mice 
that specific Sertoli cell expression of the androgen receptor also 
affects Leydig cell numbers and proliferation,55 even though in the 
present study we found no relationship between androgen receptor 
polymorphism and INSL3 expression. However, in agreement with 
Lundin et al.34 as well as with von Eckardstein et al.56 we do see a 
significant relationship between the number of androgen receptor 
trinucleotide repeats and some seminal parameters. Although they 
had not measured INSL3, the lack of relationship between AMH 
and Leydig cell parameters in the Australian men was also shown by 
Aksglaede et al.57 for a Danish cohort, suggesting that AMH may not 
be instrumental in this context.
4.4 |  Concluding remarks
In conclusion, we have made use of two mutually suppor ive co-
hort studies in men to investig e the relationship between the 
highly specific Leydig cell biomarker INSL3 an  male fertility, re-
flected in a range of seminal parameters as well as by the hormones 
of the HPG ax s. Whereas there appears o be no association be-
tween Leydig cell functional capacity a d spermatogenesis, yet 
surprisingly there is a strong correlation be ween INSL3 and FSH, 
rather than LH. Gi en the observed relationship betwe n testis 
parameters and morbidity, it will be impo tant for future studies 
to dissect the pathways of causality involved here, thus allowing 
a better understanding and a more precise interpretation of thes  
parameters.
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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1  |  INTRODUC TION
Since the first case of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
was reported in Wuhan, China, it has rapidly spread and affected 
more than 21 million people worldwide as of 17 August 2020.1 
SARS-CoV-2 uses angiotensin-converting enzyme II (ACE2) to 
enter host cells, similar to SARS-CoV, which emerged 18 years ago.2 
COVID-19 induces respiratory-predominant multiorgan dysfunc-
tion, including myocardial, renal, enteric and hepatic dysfunction, 
which coincides with the tissue expression of ACE2.3 Meanwhile, 
several studies have shown that ACE2 is expressed in human testes 
(eg spermatogonia, Leydig cells and Sertoli cells),4,5 suggesting that 
the testes may be another organ affected by COVID-19.
Numerous viruses have been detected in human semen.6 Viruses 
may persist in semen and last longer in seminal fluid than in other body 
fluids due to the immune privilege of the testes and the contribution of 
the blood-testes barrier to resistance to therapeutic agents.7,8 Semen 
may also have higher loads of viruses, such as Zika virus, than blood.9,10 
Therefore, the testes may act as a reservoir of virus, which may cause 
imprecise evaluation of viral clearance in patients. Viruses, including 
Zika virus, Ebola virus, cytomegalovirus and human immunodeficiency 
virus (HIV), have been isolated from semen and can be sexually trans-
mitted.6,11,12 Furthermore, some viruses (eg HIV, Zika virus, herpes 
simplex virus (HSV) and human papillomavirus) can adhere to or be 
internalized by spermatozoa,7,13 which may pose a risk for embryonic 
infection and cause adverse reproductive outcomes.
On the other hand, many viruses, such as mumps virus, HIV and 
HSV,7,14 have been found to impair semen quality, and they may di-
rectly interact with spermatozoa or affect spermatogenesis by in-
ducing local inflammation.15-17 Previous studies found that SARS, 
1 of the 3 epidemic coronaviruses to emerge in the past 20 years 
and that shows similar clinical presentations to COVID-19,18 could 
cause orchitis 19 and focal testicular atrophy.20 Considering the tens 
of millions of COVID-19 cases and that men are more vulnerable to 
COVID-19 than women,21-23 it is imperative to determine the effect 
of COVID-19 on male reproduction.24
Several studies have been performed on this topic. However, 
the results are controversial. For example, some researchers have 
reported that SARS-CoV-2 was not detected in the male reproduc-
tive tract,25-34 while others reported that SARS-CoV-2 RNA was 
found in the semen or testes of COVID-19 patients.35,36 There are 
also unknown factors regarding COVID-19 and male reproduction. 
Orchitis and broad destruction of the testes were found in deceased 
COVID-19 patients,35,37 while the pathological characteristics in 
survivors remain unknown. In this review, we summarize the current 
research focusing on the effects of COVID-19 on male reproduc-
tion from the following 3 aspects: detection of SARS-CoV-2 in the 
male reproductive tract, determination of the impact of COVID-19 
on sperm quality and exploration of pathological changes in the tes-
tes of COVID-19 patients. We further discuss the discrepancies and 
summarize the unknown topics, which we believe will be helpful for 
future research.
2  |  METHODS
A systematic search of published studies was conducted in the 
PubMed and Ovid Embase databases for studies published from 
December 2019 to 18 August 2020 in accordance with PRISMA.38 
All titles or abstracts of English-language studies were reviewed for 
eligibility. Citations and references of the retrieved studies were 
used as additional sources. There was no limitation on sample size, 
and case reports were included. A full-text review was performed by 
2 independent reviewers (Y.Y. and X.Y.) on studies that reported the 
detection of SARS-CoV-2 in the male reproductive tract, determined 
the impact of COVID-19 on sperm quality and explored pathologi-
cal changes in the testes of COVID-19 patients. Any disagreements 
between reviewers were discussed with a third reviewer (L.W.). 
The Cochrane RoB 2.0 tool was not applicable, and the Newcastle-
Ottawa Scale was not used due to the limited scope of the cohort 
studies among the included studies.
The literature search in PubMed used the following search terms: 
(“2019 new coronavirus” [All Fields] OR “2019 ncov” [All Fields] OR 
“severe acute respiratory syndrome coronavirus 2” [All Fields] OR 
“sars cov 2” [All Fields] OR “coronavirus disease 2019” [All Fields] 
OR “covid19” [All Fields] OR “covid 19” [All Fields]) AND (“semen” 
[All Fields] OR “sperm” [All Fields] OR “testis” [All Fields] OR “testes” 
[All Fields] OR “testicular” [All Fields] OR “epididymis” [All Fields] OR 
“spermatic fluid” [All Fields] OR “seminal fluid” [All Fields] OR “pros-
tatic secretion” [All Fields] OR “prostatic fluid” [All Fields] OR “male 
reproductive tract” [All Fields] OR “male genital tract” [All Fields]). 
Searches in Ovid Embase used the following terms: (‘2019 ncov’ OR 
‘sars cov 2’ OR ‘covid-19’ OR covid19) AND (semen OR sperm OR 
testis OR testes OR testicular OR epididymis OR ‘spermatic fluid’ OR 
‘seminal fluid’ OR ‘prostatic secretion’ OR ‘prostatic fluid’ OR ‘male 
reproductive tract’ OR ‘male genital tract’).
3  |  RESULTS AND DISCUSSION
After reviewing the studies retrieved from the database, citations 
and references were added based on a review of the title or abstract 
(Figure 1). Fourteen studies were eligible and were included in this 
study, with 12 studies detecting SARS-CoV-2 in the male reproduc-
tive tract, 3 determining the impact of COVID-19 on sperm qual-
ity and 3 exploring pathological changes in the testes of COVID-19 
patients.
3.1  |  Detection of COVID-19 in the male 
reproductive tract
Twelve studies investigated the presence of SARS-CoV-2 in the male 
reproductive tract (eg semen, prostatic secretion or testicular tis-
sue) and are shown in Table 1. Most studies were cross-sectional 
in design and included mainly Chinese subjects. In brief, ten of 12 
studies reported that none of the participants had SARS-CoV-2 RNA 
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